LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

Home・Listă Acțiuni・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Deschisă

SectorSănătate

295.43 -0.59

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

292.11

Maxim

299.71

Indicatori cheie
By Trading Economics
Venit	20M 206M
Vânzări	70M 1.2B
P/E Medie Sector	74.093 49.888
EPS	1.99
Marjă de profit	17.649
Angajați	2,500
EBITDA	7.1M 152M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+52.84% upside

Dividende
By Dow Jones
Următoarele câștiguri	30 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.7B 39B
Deschiderea anterioară	296.02
Închiderea anterioară	295.43

Sentimentul știrilor

By Acuity

50%

153 / 344 Clasament în Healthcare

Alnylam Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 iun. 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 iun. 2026, 23:45 UTC

Achiziții, Fuziuni, Preluări

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 iun. 2026, 23:43 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 iun. 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 iun. 2026, 22:06 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 iun. 2026, 20:51 UTC

Câștiguri

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 iun. 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 iun. 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 iun. 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 iun. 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 iun. 2026, 18:52 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 iun. 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 iun. 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 iun. 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 iun. 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 iun. 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 iun. 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iun. 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 iun. 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparație

Modificare preț

Alnylam Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

52.84% sus

Prognoză pe 12 luni

Medie 446.53 USD 52.84%

Maxim 550 USD

Minim 330 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAlnylam Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor Alnylam Pharmaceuticals Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

153 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.